Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 5301–5350 of 18416
On April 26, 2024, Gary W. Ferrera, the Company’s Executive Vice President and Chief Financial Officer, notified the Company of his intent to resign from the Company to pursue a professional opportunity at a privately held company.
On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. (the “ Company ”) of his resignation as the Company’s Chief Financial Officer, to be effective April 29, 2024.
submitted his resignation as CEO, effective August 1, 2024
the Board appointed Margaret ("Margi") Tooth, the Company's President, as the CEO, to be effective as of August 1, 2024.
each of Douglas Baum, QSAM's Chief Executive Officer, C. Richard Piazza, QSAM's Executive chairman, Adam King, QSAM's Chief Financial Officer, and Christopher Nelson, QSAM's General Counsel, ceased to be an executive officer
each of Douglas Baum, QSAM's Chief Executive Officer, C. Richard Piazza, QSAM's Executive chairman, Adam King, QSAM's Chief Financial Officer, and Christopher Nelson, QSAM's General Counsel, ceased to be an executive officer
the Board of Directors of the Company appointed William R. “Russ” Colvin as the Company’s President, Chief Executive Officer, and Director of the Company.
On May 2, 2024, the Company announced that Glynis Bryan intends to retire as Chief Financial Officer of Insight Enterprises, Inc. (the “Company”), effective December 31, 2024.
Effective as of the close of business on May 2, 2024, Mr. McCarthy will transition from President and Chief Executive Officer (“CEO”) of the Company to a non-executive, strategic advisory role.
On May 2, 2024, the Company announced that Karen Boone, current Chairperson of the Board, and Chris Bruzzo, a Board director, have been appointed as Interim Co-CEOs and co-Presidents of the Company, and that Jay Hoag, a Board director, has been named Chairperson of the Board, effective May 2, 2024.
On May 2, 2024, the Company announced that Karen Boone, current Chairperson of the Board, and Chris Bruzzo, a Board director, have been appointed as Interim Co-CEOs and co-Presidents of the Company, and that Jay Hoag, a Board director, has been named Chairperson of the Board, effective May 2, 2024.
Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024
Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024
Tarak Mehta would be appointed CEO on September 5, 2024
Richard G. Kyle, President and Chief Executive Officer (“CEO”) of the Company would be retiring from his position as CEO
The Board appointed Padraig McDonnell as CEO of the Company and as a member of the Company’s Board.
On May 1, 2024, Mr. McMullen retired as President and CEO of the Company and as a member of the Company’s Board.
Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.
the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024
On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.
On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.
Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.
The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.
Michael Donaghy, President and CEO of the Company will also serve as Interim Chief Financial Officer, until a replacement is appointed and qualifies.
Mr. Thomas Bellante tendered his resignation, effective April 29, 2024 (the “Effective Date”), as Chief Financial Officer of Pioneer Green Farms, Inc. (the “Company”), to pursue other business opportunities.
On April 29, 2024, the Board of Directors (the “ Board ”) of the Company appointed Deirdre Mahlan, currently serving as interim President, Chief Executive Officer and chairperson of the Board of the Company, as the non-interim President and Chief Executive Officer of the Company, effective April 30, 2024.
On April 29, 2024, Sunnova and Mr. Robert. Lane, Executive Vice President, Chief Financial Officer, confirmed the terms of Mr. Lane’s separation of employment following Mr. Lane’s expression of an intention to resign to pursue other opportunities.
Mr. Behling succeeds Akshay Jagdale, who departed the Company as its Chief Financial Officer, effective April 29, 2024, following notice received that same day.
On April 29, 2024, the Company announced the appointment of Jim Behling as the Company’s Chief Financial Officer effective April 30, 2024.
On April 29, 2024, George Gomez-Quintero, the Chief Financial Officer of the Company, notified the Company of his resignation, effective May 1, 2024.
Effective May 1, 2024, the Board appointed John C. Roiko as the Company’s Chief Financial Officer, in which capacity he will serve as the Company’s principal financial and accounting officer.
Mr. Dennis Woodside, the Company’s President, has also been appointed Chief Executive Officer of the Company
appointment of Ravi Khanna as the newly appointed Chief Executive Officer and President of the Company
On April 30, 2024, Duos Technologies Group, Inc. (the “Company”) announced the re-appointment of Adrian G. Goldfarb as Chief Financial Officer, effective April 29, 2024, following the departure of Andrew W. Murphy.
following the departure of Andrew W. Murphy, who has been recruited by another company to serve as their Chief Financial Officer.
the Board elected Craig Cornelius to serve as a member of the Board and appointed Mr. Cornelius to serve as the Chief Executive Officer of the Company, in each case effective as of the Effective Date.
Christopher S. Sotos informed Clearway Energy, Inc. (the “Company”) that, effective as of June 30, 2024 (the “Effective Date), he will move on from his position as President and Chief Executive Officer of the Company and resign from his role as a member of the Board of Directors
On April 30, 2024, Christopher S. Sotos informed Clearway Energy, Inc. (“Clearway, Inc.”), the parent company of Clearway Energy LLC (the “Company”) that, effective as of June 30, 2024 (the “Effective Date), he will move on from his position as President and Chief Executive Officer of Clearway, Inc. and the Company to pursue other opportunities.
on April 30, 2024, Craig Cornelius was appointed to serve as the Chief Executive Officer of Clearway, Inc. and the Company, effective as of the Effective Date.
the Board of Directors (the “Board”) of IPG Photonics Corporation (the “Company”) appointed Dr. Mark Gitin as Chief Executive Officer of the Company, effective June 5, 2024
Dr. Eugene Scherbakov will transition from his role as the Company’s Chief Executive Officer, effective as of June 5, 2024
Tobin Tornehl is the Company’s current principal accounting officer and, as previously announced, will be assuming the position of Vice President and Chief Financial Officer and principal financial officer, effective July 1, 2024.
Civista Bancshares, Inc. (“Civista”) announced today that Ian Whinnem will be joining Civista as Senior Vice President and Chief Financial Officer effective June 3, 2024.
As previously announced, William B. Rutherford, HCA Healthcare, Inc.’s (the “Company’s”) Executive Vice President, Chief Financial Officer, principal financial officer and principal accounting officer notified the Company of his intent to retire, effective May 1, 2024.
Chris Lundell, Chief Executive Officer, and member of the Board, stepped down as Chief Executive Officer.
appointed Thurman J. Rodgers as Chief Executive Officer, effective as of April 24, 2024
each of the Company’s named executive officers (Craig Denson, Leah Schweller, and Jim Biehl) will be separated from and will no longer be officers of the Company.
each of the Company’s named executive officers (Craig Denson, Leah Schweller, and Jim Biehl) will be separated from and will no longer be officers of the Company.
on April 25, 2024, B. Sonny Bal, MD, informed the board of directors of his intention to retire from his position as President and Chief Executive Officer of SINTX Technologies, Inc.
the previously announced appointment of Nimrod Ben-Natan as Chief Executive Officer (“CEO”) of Harmonic Inc. (the “Company”) to be effective as of June 11, 2024
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.